Table 3.
Distribution of Specific Drug Exposure Among Patients Exposed to a Cancer Drug (N=285 Unique Patients)
| Agent* | Number of Patients Exposed To Specific Drug n (%) |
|---|---|
| TOTAL | 285 (100) |
| Aminoglutethimide | 1 (0.4) |
| Anastrozole (Arimidex) | 75 (26.3) |
| Capecitabine (Xeloda) | 69 (24.2) |
| Carboplatin (Paraplatin) | 34 (11.9) |
| Cisplatin (DDP) | 1 (0.4) |
| Cyclophosphamide (Cytoxan) | 192 (67.4) |
| Docetaxel (Taxotere) | 121 (42.5) |
| Doxorubicin (Adriamycin)** | 181 (63.5) |
| Etoposide (VePesid) | 7 (2.5) |
| Exemestane (Aromasin) | 20 (7.0) |
| Florouracil | 89 (31.2) |
| Fluoxymesterone (Halotestin) | 2 (0.7) |
| Fulvestrant (Faslodex) | 13 (4.6) |
| Gefitinib (Iressa) | 1 (0.4) |
| Gemcitabine (Gemzar) | 27 (9.5) |
| Goserelin (Zoladex) | 9 (3.2) |
| Irinotecan (Camptosar) | 5 (1.8) |
| Letrozole (Femara) | 30 (10.5) |
| Leuprolide acetate (Lupron) | 1 (0.4) |
| Megestrol acetate (Megace) | 43 (15.1) |
| Methotrexate | 59 (20.7) |
| Mitoxantrone (Novantrone) | 2 (0.7) |
| Paclitaxel (Taxol) | 58 (20.4) |
| Tamoxifen | 148 (51.9) |
| Temozolomide (Temodar) | 3 (1.1) |
| Thiopeta (Thioplex) | 12 (4.2) |
| Toremifene (Fareston) | 1 (0.4) |
| Trastuzumab (Herceptin) | 35 (12.3) |
| Vincristine | 3 (1.1) |
| Vinorelbine (Navelbine) | 43 (15.1) |
*
Drugs Classified as Cardiotoxic Listed In Boldface Type
**
No Patients were Exposed to Epirubicin